Front Row Advisors’s Core Laboratories CLB Stock Holding History

Front Row Advisors’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11	Closed	-$1K	–	944
2019 Q2	$1K	Hold	11	–	–	﹤0.01%	936
2019 Q1	$1K	Hold	11	–	–	﹤0.01%	940
2018 Q4	$1K	Hold	11	–	–	﹤0.01%	916
2018 Q3	$1K	Hold	11	–	–	﹤0.01%	886
2018 Q2	$1K	Buy	+11	New	+$1.34K	﹤0.01%	930

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Front Row Advisors's CLB Position: Q3 2019 in Review

Front Row Advisors sold out of Core Laboratories (CLB) in Q3 2019, closing a stake of 11 shares — an estimated $1K sold.

Front Row Advisors first reported a position in CLB in Q2 2018 and held it in 5 quarters. The position peaked at $1K in Q2 2019. 274 funds tracked by Wall St. Rank hold CLB as of Q3 2019.

Front Row Advisors reported no remaining Core Laboratories position as of Q3 2019 after selling out during the quarter.
Front Row Advisors sold 11 Core Laboratories shares in Q3 2019, an estimated $1K.
Front Row Advisors first reported a position in Core Laboratories in Q2 2018 and held it in 5 quarters.
Front Row Advisors's Core Laboratories position peaked at $1K in Q2 2019.
274 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2019.

Based on Front Row Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.